Research Progress of the Liver–Brain Cotreatment of Depression with Supplemented Danzhi Xiaoyao Powder

Traditional Chinese medicine(TCM)has unique advantages in preventing and treating depression based on holistic concepts and syndrome differentiation and treatment.Liver depression and spleen deficiency are the main syndrome of depression.Danzhi Xiaoyao powder has the efficacy of soothing the liver and relieving depression,nourishing blood,and strengthening spleen.Present studies have proven that it has antidepressant efficacy for the syndrome of liver depression and spleen deficiency.The basic research on pharmacodynamic substances has found that the main active ingredients of Danzhi Xiaoyao powder in the treatment of depression include bupleurum saponin,paeonol,gardenoside,angelica polysaccharide,sulfate polysaccharide,paeoniflorin,albiflorin,atractylone,etc.In clinical practice,Danzhi Xiaoyao powder is often modified to make it more suitable according to the characteristics of pathogenesis and changes in the disease condition.Our research group has found that“brain and spirit failure and liver failing to disperse”are the main pathogenesis of depression.Based on the theory of“liver–brain cotreatment,”the treatment principle of“dispersing the liver and relieving depression,strengthening brain and benefiting intelligence”was put forward.On the basis of Danzhi Xiaoyao powder,Shichangpu(Acori Tatarinowii Rhizoma)was added to enlighten the mind and Yuanzhi(Polygalae Radix)to calm the mind and benefit intelligence.The modified Danzhi Xiaoyao powder was formulated,and its clinical effects on depression were remarkable.Animal experiments also confirmed that modified Danzhi Xiaoyao powder can significantly improve the depression-like behavior of depression model rats and the mechanism may be related to the regulation of the hypothalamic–pituitary–adrenal axis,the increase of the content of 5-hydroxytryptamine,and norepinephrine,which provides a reference for the further promotion of the clinical application of modified Danzhi Xiaoyao powder in the treatment of depression.

Discussion on the mechanism of Xiaoyao Powder in the treatment of irritable bowel syndrome based on network pharmacology

Objective:To predict the key components and potential targets of Xiaoyao Powder in the treatment of irritable bowel syndrome(IBS)and explore its mechanism of action in the treatment of IBS.Methods:The active components and related targets of all compounds of Xiaoyao Powder were obtained by systematic Pharmacological Analysis platform of traditional Chinese Medicine(TCMSP).The related genes of IBS were collected by Genecards and TTD.The network model of"Xiaoyao powder-compound-target-IBS"was established by Cytoscape software.STRING and Metascape platforms were used to analyze drug-disease target protein interactions and conduct network construction and module analysis.Gene Ontology(GO)function enrichment and Kyoto Encyclopedia of genes and genomes(KEGG)pathway enrichment analysis were performed on the targets.Results:In the end,149 active ingredients,267 potential targets were obtained in Xiaoyao Powder and 1751 IBS-related targets were obtained from the platforms.One hundred and sixty-five related targets were involved in the treatment of IBS by Xiaoyao Powder,among which the key targets were MMP9,VEGFA,EGF,and IL-1B,TNF,IL-6.In the GO function enrichment analysis,1976 entries were obtained for biological processes,210 entries for molecular functions,and 122 entries for cellular components;KEGG pathway enrichment analysis was performed to obtain PI3K-Akt pathway,AGE-RAGE signaling pathway,Calcium signaling pathway.Conclusion:Xiaoyao Powder may treat IBS by strengthening intestinal barrier function,reducing visceral sensitivity,inhibiting oxidative stress and inflammation.

Use of Danzhi Xiaoyao Powder in the Treatment of Diseases by Chief Physician Wang Defen: Case Examples

Danzhi Xiaoyao powder was first introduced by Xue Ji,a Ming Dynasty physician,in the“Summary of Internal Medicine.”It is primarily used for treating the syndrome of liver depression transforming into heat and is widely used in the treatment of dermatology,internal medicine,gynecology,and other multi-system diseases.This medical prescription is aptly dispensed,its detoxification effect is strong,and it is a representative medical prescription for soothing the liver,strengthening the spleen and stomach,as well as eliminating heat stagnation.Chief Physician Wang Defen inherited the academic experience of the fifth batch of nationally known Chinese medicine experts,under the guidance of Professor Ji Haiwang,a notable Chinese medicine practitioner in Shaanxi Province and Professor Shi Bingyin,a renowned endocrinologist.Through follow-up studies,the various methods and empirical prescriptions of Danzhi Xiaoyao powder applied by Chief Physician Wang Defen in the treatment of common clinical diseases are summarized.They have been proven to have conclusive efficacy,thus providing guidance and reference for the dialectical treatment using traditional Chinese medicine.

Comparative Study on Effects of Xiaoyao Powder and Its Modified Prescription on Plasma Metabolomics of Rats with Chronic Immobilization Stress＊

Objective： To determine the changes in the levels of endogenous metabolites in rats with chronic immobilization stress （CIS） taking Xiaoyao Powder （ XYP） and its modified prescription version, which lacks the volatile oils extracted from Herba Menthae. Methods： Twenty-four experimental male SD rats were randomly divided into 4 groups of 6 rats each： control, model, XYP-1 （containing volatile oils from Herba Menthae）, and XYP-2 （lacking volatile oils）. All rats except control group rats were subjected to CIS 3 h per day for 21 consecutive days. Groups XYP-1 and XYP-2 were given the extracted XYS with or without volatile oils （3.854 g/kg; suspended in distilled water） via gavage 1 h before CIS each day for 21 days. Rats were anesthetized using intraperitoneal injection of pentobarbital sodium （40 mg/kg） on the 22nd day. Observations were made using a Varian INOVA 600 MHz NMR spectrometer at 27 ~. Carr-PurcelI-Meiboom-Gill （CPMG） and longitudinal eddy-delay （LED） were applied, resulting in spectra showing only the signals from micro- and macro-metabolites. Results： Compared to controls, rats subjected to CIS showed increased levels of plasma metabolites, such as acetic acid, choline, N-glycoprotein （NAC）, saturated fatty acid, and blood sugars. Levels of low-density lipoprotein （LDL）, very low-density lipoprotein （VLDL）, and unsaturated fatty acids were decreased. The biochemical effects of XYS were characterized by elevated levels of VLDL, LDL, threonine, methionine, and glutamic acid in plasma. Conclusion： Some common and characteristic metabolites on the anti-CIS of XYP and its modified prescription were obtained. The metabolomics technology is a valuable tool and may be used to identify the specific metabolites and potential biomarkers of therapeutic effect of Chinese medicinal prescriptions.

Metabolomic characteristics of spontaneously hypertensive rats under chronic stress and the treatment effect of Danzhi Xiaoyao Powder, a traditional Chinese medicine formula

Objective: Numerous studies have demonstrated the close relationship between chronic stress and blood pressure(BP). Hypertensive subjects exhibit exaggerated reactions to stress, especially higher BP. The mechanisms by which stress affects pre-existing hypertension still need to be explored. Danzhi Xiaoyao Powder(DP), a historical traditional Chinese medicine formula, is a promising treatment for BP control in hypertensive patients under stress. The present study investigated the metabolomic disruption caused by chronic stress and the treatment effect and mechanism of DP.Methods: Spontaneously hypertensive rats(SHRs) were subjected to chronic restraint stress(CRS) for 4 weeks. BP was measured via the tail-cuff method, and anxiety-like behavior was quantified using the elevated-plus-maze test. Meanwhile, DP was administered intragastrically, and its effects were observed. Global metabolomic analysis was performed using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry, followed by multivariate statistical analysis to detect differential metabolites and pathways.Results: DP alleviated the CRS-induced increase in BP and anxiety-like behavior. Systematic metabolic differences were found among the three study groups. A total of 29 differential plasma metabolites were identified in both positive-and negative-ion modes. These metabolites were involved in triglyceride metabolism, amino acid(phenylalanine, tryptophan, and glycine) metabolism, and steroid hormone pathways.Conclusion: These findings expose the metabolomic disturbances induced by chronic stress in SHRs and suggest an innovative treatment for this disorder.

菊钩逍遥散对耳石症手法复位后肝郁型残余头晕患者血浆ET-1、CGRP及NPY水平的影响

目的观察菊钩逍遥散治疗耳石症手法复位后肝郁型残余头晕(RD)的疗效,及对血浆中内皮素-1(ET-1)、降钙素基因相关肽(CGRP)及神经肽Y(NPY)水平的影响并探讨其作用机制。方法90例患者随机分成对照组、中药组和联合组3组各30例。对照组给予甲磺酸倍他司汀片口服,中药组给予菊钩逍遥散口服,联合组给予菊钩逍遥散和甲磺酸倍他司汀片口服。治疗2周后,观察各组的临床疗效、DHI评分、SAS评分和血浆中ET-1、CGRP及NPY的变化。结果联合组总有效率为93.33%,高于中药组的82.76%和对照组的66.67%(P<0.05)。3组治疗前DHI、SAS评分、ET-1、CGRP和NPY含量比较,差别均不大(均P>0.05)。3组治疗后DHI、SAS评分均较治疗前降低(均P<0.01),且中药组、联合组的DHI、SAS评分均低于对照组(均P<0.01),而中药组和联合组DHI、SAS评分比较差别均不大(P>0.05)。3组治疗后ET-1、NPY含量均较治疗前降低(均P<0.01);中药组、联合组ET-1、NPY含量均低于对照组(均P<0.01),中药组和联合组比较,差异无统计学意义(P>0.05)。3组治疗后CGRP含量均较治疗前升高(均P<0.01),且中药组、联合组CGRP含量均高于对照组,联合组CGRP含量高于中药组(均P<0.01)。治疗过程中对照组出现2例便秘,中药组出现1例胃部不适,联合组出现1例便秘,各组均未见其他明显不良反应。结论菊钩逍遥散治疗RD疗效确切,能够缓解焦虑而改善残余头晕,其作用机制可能与调节血浆中ET-1、CGRP及NPY的水平有关。

基于网络药理学和实验验证分析逍遥散治疗黄褐斑作用机制研究

目的基于网络药理学技术及实验验证分析逍遥散治疗黄褐斑的作用机制。方法应用TCMSP等数据库和相关的文献资料,检索逍遥散的生物活性成分及相关作用靶点,构建逍遥散的药物-有效成分-作用靶点网络。基于Drugbank和Genecards等数据库建立与黄褐斑相关的疾病靶点,与逍遥散的有效成分靶点匹配获得潜在治疗靶点。根据Metascape数据库和DAVID数据库对潜在的治疗靶点进行GO生物过程、KEGG信号通路和蛋白质-蛋白质相互作用(PPI)分析,PPI网络的拓扑分析用Cytoscape软件进行。并用实验验证上述结果。结果逍遥散中有效化学成分有928种,包括白芍85种,白术55种,柴胡349种,当归125种,茯苓34种,甘草280种,有效成分作用靶点基因155个。在药物-有效成分-靶点网络内重要性前10的有效成分中,来源自柴胡4种,白芍3种,白术1种,甘草2种。共收集到49个黄褐斑相关疾病靶点,其中有24个是逍遥散治疗黄褐斑的潜在靶点基因。KEGG富集分析表明,在全部的20调信号通路中得到10条较为靠前的信号通路。GO功能富集分析显示,前10个生物过程包括分子调节功能、磷酸化等;前10个分子功能包括细胞传递部分、生物膜等;前10个细胞定位包括核苷酸、嘌呤核苷酸等。PPI网络经提取后获得了包含36个节点的核心网络,其中HSP90AA1、HSP90AB1、NTRK1、CUL3、APP、EGFR、TP53、UBC、MCM2、PRKACA基因是核心靶点。实验验证表明,逍遥散可显著改善大鼠黄褐斑情况;能升高血清SOD水平,降低血清Tyr和MDA含量;改善黄褐斑处皮肤组织结构和皮肤HMB45表达情况。结论逍遥散可通过多成分、多靶点和多通路治疗黄褐斑,起治疗作用的有效成分主要来源自柴胡、白芍、白术和甘草,而核心靶点主要有HSP90AA1等基因。

丹栀逍遥散联合和调督任安神针刺法对卒中后抑郁患者的临床疗效

目的探讨丹栀逍遥散联合和调督任安神针刺法对卒中后抑郁患者的临床疗效。方法98例患者随机分为对照组和观察组,每组49例,对照组给予常规治疗,观察组在对照组基础上加用丹栀逍遥散联合和调督任安神针刺法,疗程4周。检测临床疗效、MoCA评分、肠道菌群(肠球菌、乳酸杆菌、大肠埃希菌、双歧杆菌)、免疫功能指标(IgM、IgG、IgA)、抑郁状态指标(HAMD评分、SDS评分)、不良反应发生率变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,2组MoCA评分、免疫功能指标升高(P<0.05),HAMD评分、SDS评分降低(P<0.05),肠球菌、大肠埃希菌减少(P<0.05),乳酸杆菌、双歧杆菌增加(P<0.05),以观察组更明显(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论丹栀逍遥散联合和调督任安神针刺法可安全有效地改善卒中后抑郁患者认知功能和体液免疫,调节肠道菌群,减轻抑郁症状。

丹栀逍遥散加减方对精神分裂症患者高催乳素血症的影响研究

目的观察丹栀逍遥散加减方对精神分裂症患者高催乳素水平的影响。方法将118例精神分裂症并发有高催乳血症患者按照随机数字表法分为2组,2组均常规给予抗精神分裂症药物治疗,治疗组56例予丹栀逍遥散加减方治疗,对照组62例予安慰剂治疗。2组均治疗12周后。比较2组治疗前及治疗4、12周血清催乳素、精神症状[采用阳性和阴性症状量表(PANSS)评分进行评价]及生活质量[采用精神分裂症患者生活质量量表(SQLS)进行评价,包括心理社会、动机/精力、症状/副反应3个方面]变化情况,统计分析治疗组治疗12周后血清催乳素水平与PANSS评分、SQLS评分之间的相关性。结果与本组治疗前比较,治疗组治疗4、12周血清催乳素水平均降低(P<0.05),且治疗组治疗4、12周血清催乳素水平均低于对照组同期(P<0.05),但对照组治疗4、12周血清催乳素水平与治疗前比较差异均无统计学意义(P>0.05)。2组治疗4、12周PANSS评分与本组治疗前比较及组间比较差异均无统计学意义(P>0.05)。与本组治疗前比较,治疗组治疗4、12周SQLS心理社会、动机/精力、症状/副反应评分及总分均降低(P<0.05),且治疗组治疗4、12周SQLS心理社会、动机/精力、症状/副反应评分及总分均低于对照组同期(P<0.05),但对照组治疗4、12周SQLS心理社会、动机/精力、症状/副反应评分及总分与治疗前比较差异均无统计学意义(P>0.05)。经Pearson相关性分析显示,治疗组治疗12周血清催乳素水平与SQSL症状/副反应评分及总分存在正相关性(r=0.259,P=0.005;r=0.263,P=0.004)。结论丹栀逍遥散加减方治疗精神分裂症患者高催乳素血症临床疗效确切,可有效降低患者血清催乳素水平,提高患者生活质量,是一种颇具治疗效应的临床辅助治疗手段。

逍遥散方质量控制技术研究进展

逍遥散方为治疗妇科诸疾、郁证的代表方,由柴胡、当归、茯苓、白芍、白术、甘草、生姜、薄荷8味饮片组成,具有疏肝解郁、养血健脾的功效。文章就近10年来逍遥散方在制备工艺、鉴别技术、含有量测定等方面出现的新方法、新技术进行归纳总结,以期为该方制剂的质量控制及进一步开发应用提供科学依据。

基于网络药理学研究丹栀逍遥散治疗便秘的作用机制

目的基于网络药理学研究丹栀逍遥散治疗便秘的作用机制。方法利用TCMSP、BATMAN-TCM、Uniprot、GeneCards等数据库检索筛选丹栀逍遥散关键成分及相关靶点、疾病靶点和相关通路。通过STRING数据库和Cytoscape软件绘制PPI网络图,寻找核心基因。利用Metascape和BioGPS数据库通过微生信平台进行基因富集分析。利用SwissDock平台进行分子对接分析。结果丹栀逍遥散药物靶点746个,便秘靶点1620个。关键靶点为VEGFA、CASP3、TNF、JUN,关键成分为槲皮素、β-谷甾醇、山奈酚、豆甾醇。关键靶点主要作用于淋巴细胞、平滑肌、结肠、结直肠腺癌、小肠,主要富集于炎性肠病、NF-κB信号通路等。分子对接结果显示活性成分与靶点蛋白结合稳定。结论丹栀逍遥散治疗便秘的作用机制,可能是通过其4个关键成分作用于4个关键靶点,调节多通路,起到抑制炎症、保护肠黏膜屏障、调节肠道菌群等作用。

逍遥散及其类方治疗干眼的研究进展

近年来,干眼发病率不断上升,越来越多人的生活质量因干眼受到影响。逍遥散以疏肝养血之效治疗眼病历史悠久,近年来在干眼治疗中的应用也逐渐增多。本文总结了以逍遥散为基础进行加减化裁的方剂在治疗普通干眼、围绝经期干眼、糖尿病性干眼、睑板腺功能障碍型干眼中的临床应用进展,发现逍遥散及其类方在治疗各种类型的干眼上疗效显著,其作用机制包括调节相关炎症因子、影响性激素、增加杯状细胞数量、减少角膜上皮细胞凋亡等,在临床上有重要的应用价值。

丹栀逍遥散合甘麦大枣汤联合疏肝调神针法对偏头痛临床疗效及血清指标变化的影响

目的 分析丹栀逍遥散合甘麦大枣汤联合疏肝调神针法对偏头痛临床疗效及对血清肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)、细胞间黏附分子-1(intercellular adhesion molecule-1,ICAM-1)和降钙素基因相关肽(Calcitonin gene related peptide, CGRP)水平的影响。方法 选择齐齐哈尔市中医医院2020年3月—2022年3月收治的126例偏头痛患者,使用随机数字表法分别纳入联合组(n=63)、对照组(n=63)。两组均给予盐酸氟桂利嗪片口服,并给予疏肝调神针法针灸治疗,联合组加用丹栀逍遥散合甘麦大枣汤,持续1个月。对比两组治疗前后头痛症状、生活质量变化,并比较两组治疗前后脑血流动力学、血清指标变化,分析两组临床疗效。结果 头痛症状方面,两组治疗1个月后头痛发作频率、每月无头痛天数、发作时疼痛视觉模拟评分(Visual Analog Scale, VAS)、单次头痛持续时间均较治疗前下降;联合组治疗1个月后头痛发作频率、每月无头痛天数、发作时VAS评分、单次头痛持续时间均低于对照组,差异有统计学意义(P<0.05)。生活质量方面,两组治疗1个月后偏头痛生活品质问卷(Migraine-SpecificQualityLifeQuestionnaire, MSQ)量表各维度评分及总分均较治疗前下降;联合组治疗1个月后MSQ量表各维度评分及总分均低于对照组,差异有统计学意义(P<0.05)。脑血流动力学方面,两组治疗1个月后双侧大脑中动脉(middle cerebral artery, MCA)、基底动脉(Basilar artery, BA)、大脑后动脉(Posterior cerebral artery, PCA)、大脑前动脉(Anterior cerebral artery, ACA)血流速度均较治疗前下降;联合组治疗1个月后MCA、BA、PCA、ACA血流速度均低于对照组,差异有统计学意义(P<0.05)。血清指标方面,两组治疗1个月后血清TNF-α、ICAM-1、CGRP均较治疗前下降;联合组治疗1个月后血清TNF-α、ICAM-1、CGRP均低于对照组,差异有统计学意义(P<0.05)。联合组治疗1个月后总有效率为90.48%,高于对照组的74.60%,差异有统计学意义(P<0.05)。结论 在疏肝调神针法的基础上,将丹栀逍遥散合甘麦大枣汤应用于偏头痛的治疗,不仅有助于改善患者头痛症状、脑血流动力学、生活质量,也能够改善血清TNF-α、ICAM-1、CGRP,从而达到更为理想的临床疗效。

逍遥散抗抑郁作用的研究进展

抑郁症是目前高发的一种慢性和危及生命的精神疾病,逍遥散是其常用的治疗方剂,大量临床研究和动物实验已证实其有确切的抗抑郁效果,其抗抑郁的作用机制也在广泛研究当中。从逍遥散抗抑郁的临床应用、逍遥散抗抑郁的作用机制这两方面阐述逍遥散抗抑郁作用的研究现状,研究发现逍遥散可用于多种类型抑郁症的治疗或辅助治疗,比如产后抑郁症、轻中度抑郁症、围绝经期抑郁症等等,逍遥散的抗抑郁作用可能是通过调节单胺类神经递质的水平、调控下丘脑-垂体-肾上腺轴(hypothalamic-pituitary-adrenal axis, HPA)、调节细胞因子抑郁质免疫炎症反应、提高脑源性神经营养因子(brain-derived neurotrophic factor, BDNF)表达水平、调节α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(α-amino-3-hydroxy-5-methyl-4-isoxazole-propionicacid receptor, AMPA)受体水平改善神经可塑性,以及调节“微生物-肠-脑”轴等多种途径实现。通过对近10年有关逍遥散治疗抑郁症的研究的总结和归纳分析,发现逍遥散抗抑郁的临床研究缺乏多中心、大样本、高质量的临床随机双盲对照试验,其次,逍遥散抗抑郁作用的机制研究太宽泛而不够深入,逍遥散对于每一条途径都有其调节作用,但能否影响多种途径间的相互作用,还有待于进一步深入研究和挖掘。故此,以期为逍遥散抗抑郁的深入研究提供更多思路,为逍遥散的研发提供更多方向和选择,充分展现中医药临床治疗的优势及特色。

基于“肝病实脾”理论探讨逍遥散对肝纤维化大鼠肝星状细胞铁死亡的影响

目的:基于“肝病实脾”理论探讨逍遥散对肝纤维化大鼠肝星状细胞铁死亡的影响。方法:采用腹腔注射四氯化碳的方法建立肝纤维化大鼠模型,随机分为模型组、逍遥散组、水飞蓟宾葡甲胺组,每组12只,另选12只SD大鼠腹腔注射等剂量玉米油设为对照组,以逍遥散、水飞蓟宾葡甲胺分组处理后检测各组大鼠肝功能指标天冬氨酸氨基转移酶(AST)和丙氨酸氨基转移酶(ALT);检测各组大鼠肝指数并以Masson染色检测各组大鼠肝纤维化,比较其肝胶原容积分数(CVF);以免疫组织化学染色检测各组大鼠肝星状细胞活化,比较其肝组织α-SMA阳性表达;通过16SrRNA基因测序检测各组大鼠肠道菌群改变。分离培养上述各组大鼠原代肝星状细胞(HSC),以试剂盒测定各组大鼠HSC铁死亡指标:铁含量、谷胱甘肽(GSH)及丙二醛(MDA)水平;以免疫印迹法检测各组大鼠HSC铁死亡标志蛋白[长链脂酰辅酶A合成酶4(ACSL4)、环加氧酶2(PTGS2)、谷胱甘肽过氧化酶4(GPX4)]表达。结果:与对照组相比,模型组大鼠拟杆菌目丰度、HSC铁含量、MDA水平、ACSL4与PTGS2蛋白表达均明显降低(P<0.05),血清AST与ALT水平、肝指数、肝CVF、肝组织α-SMA阳性比、ACE指数、梭菌目丰度、HSC中GSH水平与GPX4蛋白表达均明显升高(P<0.05);与模型组相比,逍遥散组、水飞蓟宾葡甲胺组大鼠拟杆菌目丰度、HSC铁含量、MDA水平、ACSL4与PTGS2蛋白表达均升高(P<0.05),血清AST与ALT水平、肝指数、肝CVF、肝组织α-SMA阳性比、ACE指数、梭菌目丰度、HSC中GSH水平与GPX4蛋白表达均降低(P<0.05);与逍遥散组相比,水飞蓟宾葡甲胺组大鼠各指标差异无统计学意义(P>0.05)。结论:逍遥散可通过诱导肝星状细胞铁死亡而抑制其活性,进而减轻肝纤维化大鼠肝组织肝纤维化,减轻其肝功能损伤,最终对大鼠发挥明显肝保护作用。

逍遥散及其拆方对Erastin诱导的LO-2肝细胞系铁死亡的影响

目的 探讨逍遥散及其拆方对Erastin诱导肝细胞铁死亡的影响及机制。方法 使用铁死亡诱导剂Erastin诱导肝细胞LO-2铁死亡,用逍遥散及各功效拆方(逍遥散去疏肝药组、逍遥散去健脾药组、逍遥散去养血药组)的含药血清进行干预,阳性对照药使用铁死亡抑制剂Ferrostatin-1。通过CCK-8检测细胞活力,ELISA法检测细胞上清液中谷丙转氨酶(alanine aminotransferase,ALT)、谷草转氨酶(aspartate aminotransferase,AST)水平,比色法检测细胞中丙二醛(malondialdehyde,MDA)、还原型谷胱甘肽(reduced glutathione,GSH)、Fe^(2+)等含量,荧光酶标仪检测脂质过氧化活性氧(reactive oxygen species,ROS),RT-PCR检测细胞中谷胱甘肽过氧化物酶4(glutathione peroxidase 4,GPX4)、前列腺素内过氧化物合酶2(prostaglandin-endoperoxide synthase 2,PTGS2)、铁调素(hepcidin)、膜铁转运蛋白(ferroportin,FPN1)mRNA表达,Western blot检测细胞中骨形态发生蛋白6(bone morphogenetic protein6,BMP6)、铁调素调节蛋白(hemojuvelin,HJV)、Smad同源物4(mothers against decapentaplegic homolog 4,SMAD4)蛋白表达。结果 erastin诱导肝细胞铁死亡后,细胞活力较对照组显著下降(P<0.05),细胞外上清液中ALT、AST含量显著上升(P<0.05),细胞中MDA、ROS、Fe^(2+)、PTGS2与hepcidin mRNA表达及BMP6/HJV/Smad4信号通路蛋白显著上升(P<0.05),GSH含量及GPX4、FPN1 mRNA表达显著下降(P<0.05)。除逍遥散去养血药组在Smad4蛋白表达方面与模型组无显著差异(P>0.05),逍遥散及各功效拆方及阳性对照药Ferrostatin-1均能显著逆转上述指标的变化(P<0.05)。与整方组疗效比较,逍遥散去疏肝药组AST、MDA、GSH、ROS、Fe^(2+)、BMP6、hepcidin、FPN1指标具有显著差异(P<0.05);除逍遥散去健脾药组在Smad4蛋白表达方面与整方组无显著差异(P>0.05),逍遥散去健脾药组及逍遥散去养血药组对所检测指标均有显著改善(P<0.05)。结论 逍遥散可抑制Erastin诱导的肝细胞铁死亡,其机制可能与调控BMP6/HJV/SMAD4信号通路及其下游hepcidin-ferroportin轴有关,而逍遥散各功效拆方均在一定程度上参与了逍遥散抑制肝细胞铁死亡的过程。

丹栀逍遥散在眼科中应用的研究进展

丹栀逍遥散擅治肝郁血虚之证,作为中医眼科常用方剂,深入研究该方对挖掘本方的临床价值有重要意义。对该方从古至今进行梳理,发现其临床应用范围逐渐扩大,且在中医眼科中较为常用。本文综述了丹栀逍遥散的现代临床应用,总结相关药理作用与作用机制,发现丹栀逍遥散可以通过抗炎、调节细胞免疫、神经保护等方式干预干眼、视神经疾病、葡萄膜炎等眼病,具有较好疗效。但中医药治疗疾病常通过多成分、多途径、多靶点发挥作用,丹栀逍遥散作用机制尚待进一步完善,本研究可为今后丹栀逍遥散在眼科中的应用提供参考。

基于一气周流理论浅析逍遥散治疗闭经

黄元御一气周流理论以“中土为轴,四象为轮”为基本框架结构,将人体生理病理与“土枢四象”的周流运转联系起来,为中医临床诊治疾病提供一种新的思路。逍遥散源自《太平惠民和剂局方》,在妇科病闭经的临床治疗方面起到了很好的效果,其方药组成可通过升木达郁、培补土气来恢复“一气周流”,而改善闭经“木气郁陷、中土气虚”的病机,恢复月经来潮。

丁雷应用丹栀逍遥散联合消瘰丸治疗良性甲状腺结节经验

作者总结丁雷主任医师在临床中观察良性甲状腺患者的病因病机及治疗经验。丁主任认为,良性甲状腺结节病机以肝气郁滞为本,痰火瘀搏结于颈前为核心,故以化痰散结、泻火逐瘀,疏肝解郁的治疗原则贯穿于整个病程,运用丹栀逍遥散联合消瘰丸治疗。在临床中根据患者病情灵活运用以治疗良性甲状腺结节患者,取得了较好的临床疗效,后附验案说明,为治疗良性甲状腺结节提供新思路。

生物信息学引导下的逍遥散抗抑郁作用分析

目的通过生物信息学方法分析逍遥散抗抑郁作用的潜在机制。方法收集逍遥散药物的化学成分,筛选抑郁症疾病相关靶点,构建逍遥散“成分-靶点”网络和“化合物靶点-抑郁症疾病靶点”相互作用网络,进行网络聚类分析。基于毒药物动力学进行逍遥散活性成分筛选,并将具有高亲和力的化合物与靶点蛋白进行虚拟分子对接。结果逍遥散的“成分-靶点”网络包括357个化学成分节点、815个潜在作用靶点节点以及8109条相互作用关系,“化合物靶点-抑郁症疾病靶点”网络共含有847个节点和13622个相互作用关系。网络聚类分析共获得23个子网络,有8个子网络中含有逍遥散与抑郁症共同具有的靶点蛋白。毒药物动力学筛选共获得4个关键靶点及其对应的10个活性成分。结论评分最高的子网络相关靶点显著富集于环磷酸腺苷(cyclic adenosine monophosphate,cAMP)信号通路,可能是逍遥散抗抑郁功能网络发挥作用的关键途径,筛选出逍遥散中10个活性化合物具有潜在抗抑郁作用。